A fertility monitoring company has attracted substantial investment. This funding aims to enhance product development and market reach.
Fertility Focus, a pioneer in ovulation prediction technology, has received a significant boost from investors.
Investment Details
Fertility Focus has secured £2 million in growth capital investment. This substantial funding round was led by Foresight, contributing £1.25 million. The capital will support the development and marketing of an advanced fertility monitoring device.
Company Background
The OvuSense device, a registered medical device, was developed to commercialise this technology. This device is designed to assist women in predicting their ovulation cycle accurately.
Technology Behind OvuSense
FFL’s technology is specifically aimed at over 4 million women who face difficulties in conceiving. The device is recognised for its 99 per cent accuracy in real-time ovulation prediction.
Management Team
Non-executive Chairman Steve Godber supports the team. Godber brings a wealth of knowledge from his tenure at Vickers Medical and Forum Bioscience.
Investment Utilisation
FFL’s leadership is optimistic about the growth opportunities this investment unlocks. The partnership with Foresight is seen as pivotal for the company’s market expansion.
Investor’s Perspective
Jones stated, “FFL is a well-run business that has developed an innovative, clinically supported, and IP rich product in OvuSense.”
Future Prospects
Milnes remarked, “We are thrilled to be working with Foresight to grow our team and accelerate our sales and marketing activity.”
The £2 million investment in Fertility Focus signifies a promising future for the company. With robust support from Foresight, Fertility Focus is set for substantial growth and innovation.
This funding will not only enhance the development of OvuSense but also expand its market reach, benefiting millions of women facing fertility challenges.